The Company does not own or operate manufacturing facilities for the production of Gimoti, nor does it plan to develop its own manufacturing operations in the foreseeable future. The Company currently depends on third-party contract manufacturers for all of its required raw materials, drug substance and finished product for its preclinical research and clinical trials. Other than an agreement with Cosma S.p.A. to supply metoclopramide for the manufacture of Gimoti, the Company does not have any other contractual relationships for the manufacture of commercial supplies of Gimoti. If Gimoti is approved by any regulatory agency, the Company intends to enter into agreements with third-party contract manufacturers for the commercial production at that time. The Company currently utilizes a third-party consultant, which it engages on an as-needed, hourly basis, to manage its manufacturing contractors.
I suspect because it's a contractual obligation, they may want to conceal how much they're actually paying for this product because they may be renegotiating the price in preparation of their NDA submission, and the eventual (or hopeful) approval by the FDA. This isn't looking good for the shorts! It's not a matter of IF this drug will be granted FDA approval, but WHEN. Hang onto your shorts! All IMVHO of course! GLTA!
Recent EVOK News
- Evoke Pharma to Present Additional GIMOTI Healthcare Utilization Data Focused on Gastroparesis Care Insights in Women at 2024 Digestive Disease Week (DDW) Conference • GlobeNewswire Inc. • 05/16/2024 08:02:24 PM
- Form ARS/A - Annual Report to Security Holders: [Amend] • Edgar (US Regulatory) • 05/14/2024 08:58:19 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:20:33 PM
- Evoke Pharma Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/14/2024 08:15:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:15:18 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 05/14/2024 08:05:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:00:15 PM
- Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications • GlobeNewswire Inc. • 04/17/2024 12:30:27 PM
- Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D’Onofrio to Chief Executive Officer • GlobeNewswire Inc. • 03/21/2024 08:15:59 PM
- Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/14/2024 08:05:28 PM
- Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024 • GlobeNewswire Inc. • 03/07/2024 09:10:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2024 09:15:06 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/20/2024 09:38:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 02:00:04 PM
- Evoke Pharma Announces Closing of $7.5 Million Public Offering • GlobeNewswire Inc. • 02/14/2024 12:30:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2024 10:15:35 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 02/09/2024 10:14:30 PM
- Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million • GlobeNewswire Inc. • 02/09/2024 12:30:48 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/08/2024 11:50:59 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/11/2024 02:38:48 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/04/2024 09:30:47 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 12/19/2023 01:30:35 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 12/15/2023 09:30:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/29/2023 02:00:07 PM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM